Pharmacological treatment of migraine: Drug classes, mechanisms of action, clinical trials and new treatments
- PMID: 34379793
- DOI: 10.1111/bph.15657
Pharmacological treatment of migraine: Drug classes, mechanisms of action, clinical trials and new treatments
Abstract
Migraine is the sixth most prevalent disease globally, a major cause of disability, and it imposes an enormous personal and socio-economic burden. Migraine treatment is often limited by insufficient therapy response, leading to the need for individually adjusted treatment. In this review, we analyse historical and current pharmaceutical development approaches in acute and chronic migraine based on a comprehensive and systematic analysis of Food and Drug Administration (FDA)-approved drugs and those under investigation. The development of migraine therapeutics has significantly intensified during the last 3 years, as shown by our analysis of the trends of drug development between 1970 and 2020. The spectrum of drug targets has expanded considerably, which has been accompanied by an increase in the number of specialised clinical trials. This review highlights the mechanistic implications of FDA-approved and currently investigated drugs and discusses current and future therapeutic options based on identified drug classes of interest.
Keywords: 5-HT; CGRP; clinical trials; migraine; migraine acute treatment; migraine chronic treatment.
© 2021 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Similar articles
-
Update on the Pharmacological Treatment of Chronic Migraine.Curr Pain Headache Rep. 2016 Jan;20(1):6. doi: 10.1007/s11916-015-0533-9. Curr Pain Headache Rep. 2016. PMID: 26728188 Review.
-
Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans.Pharmacol Ther. 2020 Jul;211:107528. doi: 10.1016/j.pharmthera.2020.107528. Epub 2020 Mar 12. Pharmacol Ther. 2020. PMID: 32173558 Review.
-
History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.Headache. 2018 Nov;58 Suppl 3:238-275. doi: 10.1111/head.13379. Epub 2018 Sep 22. Headache. 2018. PMID: 30242830 Review.
-
Pharmacological synergy: the next frontier on therapeutic advancement for migraine.Headache. 2012 Apr;52(4):636-47. doi: 10.1111/j.1526-4610.2011.02058.x. Epub 2012 Jan 6. Headache. 2012. PMID: 22221151 Review.
-
Calcitonin gene related peptide in migraine: current therapeutics, future implications and potential off-target effects.J Neurol Neurosurg Psychiatry. 2021 Dec;92(12):1325-1334. doi: 10.1136/jnnp-2020-324674. Epub 2021 Jan 25. J Neurol Neurosurg Psychiatry. 2021. PMID: 33495299 Review.
Cited by
-
Acupoints for Headache with Blood Stasis Syndrome: a Literature Study Based on Data Mining Technology.J Pain Res. 2024 Jul 26;17:2455-2471. doi: 10.2147/JPR.S471441. eCollection 2024. J Pain Res. 2024. PMID: 39081327 Free PMC article. Review.
-
Genistein mitigates nitroglycerine-induced migraine: modulation of nitric oxide-mediated vasodilation and oxidative stress.Metab Brain Dis. 2024 Jun;39(5):821-831. doi: 10.1007/s11011-024-01360-5. Epub 2024 May 25. Metab Brain Dis. 2024. PMID: 38795260
-
Untangling the mess of CGRP levels as a migraine biomarker: an in-depth literature review and analysis of our experimental experience.J Headache Pain. 2024 Apr 29;25(1):69. doi: 10.1186/s10194-024-01769-4. J Headache Pain. 2024. PMID: 38684990 Free PMC article. Review.
-
Review of Personalized Medicine and Pharmacogenomics of Anti-Cancer Compounds and Natural Products.Genes (Basel). 2024 Apr 8;15(4):468. doi: 10.3390/genes15040468. Genes (Basel). 2024. PMID: 38674402 Free PMC article. Review.
-
Migraine and Its Treatment from the Medicinal Chemistry Perspective.ACS Pharmacol Transl Sci. 2024 Mar 16;7(4):951-966. doi: 10.1021/acsptsci.3c00370. eCollection 2024 Apr 12. ACS Pharmacol Transl Sci. 2024. PMID: 38633587 Review.
References
REFERENCES
-
- Ailani, J., Lipton, R. B., Hutchinson, S., Knievel, K., Lu, K., Butler, M., Yu, S. Y., Finnegan, M., Severt, L., & Trugman, J. M. (2020). Long-term safety evaluation of ubrogepant for the acute treatment of migraine: Phase 3, randomized, 52-week extension trial. Headache, 60(1), 141-152. https://doi.org/10.1111/head.13682
-
- Akerman, S., & Goadsby, P. J. (2005). Topiramate inhibits trigeminovascular activation: An intravital microscopy study. British Journal of Pharmacology, 146(1), 7-14. https://doi.org/10.1038/sj.bjp.0706290
-
- Akopian, A. N., Chen, C. C., Ding, Y., Cesare, P., & Wood, J. N. (2000). A new member of the acid-sensing ion channel family. Neuroreport, 11(10), 2217-2222. https://doi.org/10.1097/00001756-200007140-00031
-
- Alexander, S. P. H., Christopoulos, A., Davenport, A. P., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., & Pawson, A. J. (2019). THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology, 176, S21-S141. https://doi.org/10.1111/bph.14748
-
- Alexander, S. P. H., Fabbro, D., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., Sharman, J. L., & Southan, C. (2019). THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes. British Journal of Pharmacology, 176, S297-S396. https://doi.org/10.1111/bph.14752
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials